{"analyses":[{"ciLowerLimit":"67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"91","groupDescription":"The primary endpoint is progression-free survival time, with progression defined as a patient having evidence of recurrent LMS on follow-up evaluation and CT scan. Futility monitoring will be based on the accumulating right-censored PFS time data. The monitoring rules will be based on a Bayesian model.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.15","paramType":"Two year PFS","paramValue":"78","statisticalMethod":"Bayesian Posterior Probability","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67","upperLimit":"91","value":"78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"Women Treated With Adjuvant Regimen for High Risk Uterine LMS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 3 months up to two years","title":"Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS","type":"PRIMARY","unitOfMeasure":"percentage of participants"}